BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torky A, Sinaii N, Jha S, Desai J, El-Maouche D, Mallappa A, Merke DP. Cardiovascular Disease Risk Factors and Metabolic Morbidity in a Longitudinal Study of Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 2021;106:e5247-57. [PMID: 33677504 DOI: 10.1210/clinem/dgab133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Schröder MAM, Claahsen-van der Grinten HL. Novel treatments for congenital adrenal hyperplasia. Rev Endocr Metab Disord 2022. [PMID: 35199280 DOI: 10.1007/s11154-022-09717-w] [Reference Citation Analysis]
2 Kim MS, Fraga NR, Minaeian N, Geffner ME. Components of Metabolic Syndrome in Youth With Classical Congenital Adrenal Hyperplasia. Front Endocrinol 2022;13:848274. [DOI: 10.3389/fendo.2022.848274] [Reference Citation Analysis]
3 Lim SG, Lee YA, Jang HN, Kong SH, Ahn CH, Kim SW, Shin CH, Kim JH. Long-Term Health Outcomes of Korean Adults With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Front Endocrinol (Lausanne) 2021;12:761258. [PMID: 34712205 DOI: 10.3389/fendo.2021.761258] [Reference Citation Analysis]
4 Barbot M, Mazzeo P, Lazzara M, Ceccato F, Scaroni C. Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia. Front Endocrinol 2022;13:934675. [DOI: 10.3389/fendo.2022.934675] [Reference Citation Analysis]
5 Takasawa K, Kashimada K. Toward Improving the Transition of Patients With Congenital Adrenal Hyperplasia From Pediatrics to Adult Healthcare in Japan. Front Pediatr 2022;10:936944. [DOI: 10.3389/fped.2022.936944] [Reference Citation Analysis]